Matches in Wikidata for { <http://www.wikidata.org/entity/Q89725043> ?p ?o ?g. }
- Q89725043 description "articolo scientifico (pubblicato il 2020)" @default.
- Q89725043 description "artikull shkencor i botuar më 01 shkurt 2020" @default.
- Q89725043 description "artículu científicu espublizáu en febreru de 2020" @default.
- Q89725043 description "im Februar 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q89725043 description "scientific article published on 01 February 2020" @default.
- Q89725043 description "wetenschappelijk artikel" @default.
- Q89725043 description "наукова стаття, опублікована 1 лютого 2020" @default.
- Q89725043 description "գիտական հոդված հրատարակված 2020 թվականի փետրվարի 1-ին" @default.
- Q89725043 name "Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer" @default.
- Q89725043 name "Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer" @default.
- Q89725043 name "Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer" @default.
- Q89725043 type Item @default.
- Q89725043 label "Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer" @default.
- Q89725043 label "Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer" @default.
- Q89725043 label "Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer" @default.
- Q89725043 prefLabel "Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer" @default.
- Q89725043 prefLabel "Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer" @default.
- Q89725043 prefLabel "Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer" @default.
- Q89725043 P1433 Q89725043-C8202BF6-8440-41DD-A380-49E3011C2E4B @default.
- Q89725043 P1476 Q89725043-9DCAA58A-8049-44A2-A398-671E9A7449B9 @default.
- Q89725043 P2093 Q89725043-0B0EAAFB-9B4C-4F94-9F82-7B271EF60F9E @default.
- Q89725043 P2093 Q89725043-28A29FDB-C5DB-4461-A6F9-CF839672EF00 @default.
- Q89725043 P2093 Q89725043-2EBFED5F-CA15-46AB-B599-24D857E8A20A @default.
- Q89725043 P2093 Q89725043-36562325-BFAE-42E7-AB3D-0C1B35BD111F @default.
- Q89725043 P2093 Q89725043-55116953-6818-4978-BA2F-2AB6B335E8C8 @default.
- Q89725043 P2093 Q89725043-6A991CAF-4626-4E0B-B5EC-7C73F1F93C32 @default.
- Q89725043 P2093 Q89725043-B0DA8FBD-1AC1-41DF-B7E0-977E9BEA98E5 @default.
- Q89725043 P2093 Q89725043-C4511AE2-5AAD-40A7-B6FA-B3E2B980D968 @default.
- Q89725043 P2093 Q89725043-ED4F385B-3F77-4E94-95D4-264B3C9D930B @default.
- Q89725043 P2093 Q89725043-FC1E3AD8-EE19-45DF-A3BF-9F4CDBE9526E @default.
- Q89725043 P2860 Q89725043-04089E2A-0DD0-434A-9158-E2ABFFB01363 @default.
- Q89725043 P2860 Q89725043-08DA30CC-120A-4D59-944F-60A713B35D75 @default.
- Q89725043 P2860 Q89725043-0E604A7C-5FA5-4A9F-B6A9-F8842A0833DF @default.
- Q89725043 P2860 Q89725043-0E8819A4-560C-43D1-92CF-0921A6EC9ED8 @default.
- Q89725043 P2860 Q89725043-105DACEF-1717-4343-8121-3AB2F1D9F52B @default.
- Q89725043 P2860 Q89725043-17419F12-0B8C-4047-A559-5DEE6EFA31EA @default.
- Q89725043 P2860 Q89725043-1E6ADFCD-5C57-4B0F-AB94-4A21E2B11A5E @default.
- Q89725043 P2860 Q89725043-1E6DCBD1-8902-45F3-A7BC-9B2AF8876EDC @default.
- Q89725043 P2860 Q89725043-38D09363-A9FB-4A46-B918-94EE5357235C @default.
- Q89725043 P2860 Q89725043-39A76E6B-AF3F-4C7A-9F52-D4050B08AFBB @default.
- Q89725043 P2860 Q89725043-3F779AB2-F03D-4FDB-A09C-528A0BAC8FE6 @default.
- Q89725043 P2860 Q89725043-40E264AF-3710-47BE-A82F-2315DA155E70 @default.
- Q89725043 P2860 Q89725043-721C01D9-CC0E-402F-8708-AABC68CE2B41 @default.
- Q89725043 P2860 Q89725043-7A5C27DE-13EC-468E-A9FC-2ADE0AE8E5A4 @default.
- Q89725043 P2860 Q89725043-7C3E9B08-CEB7-4F6F-827C-63E41F301A78 @default.
- Q89725043 P2860 Q89725043-7D2246E3-9D51-490F-AC44-68D93EAB5FC4 @default.
- Q89725043 P2860 Q89725043-8561312C-D9ED-4694-AF0C-095C418E28F3 @default.
- Q89725043 P2860 Q89725043-867B5C14-9C8D-4378-9159-B1C715E1090E @default.
- Q89725043 P2860 Q89725043-87B65082-958B-4454-A14C-437CBDED8ECB @default.
- Q89725043 P2860 Q89725043-8BC667B1-95ED-4A98-9CE7-4E5A5DD1091E @default.
- Q89725043 P2860 Q89725043-8CB37934-F2CE-4B46-B772-7FCA0FB9685A @default.
- Q89725043 P2860 Q89725043-9528191D-AB38-4994-A90E-C0C0CBA27A4B @default.
- Q89725043 P2860 Q89725043-9B02551E-DDC6-40A7-B6ED-8C6939CB1F6C @default.
- Q89725043 P2860 Q89725043-A63EC7C6-7C1E-4F8C-A2CA-4344F965B4FC @default.
- Q89725043 P2860 Q89725043-B09BF950-F7E5-44CA-B644-64B63D86B4CA @default.
- Q89725043 P2860 Q89725043-B8B0F5E5-E6BE-46E8-8D63-653592FFF682 @default.
- Q89725043 P2860 Q89725043-BC43539C-7F83-4E79-98A6-72F87CA9EF7D @default.
- Q89725043 P2860 Q89725043-DB38D609-D9BB-468F-8535-3531CE8DAE14 @default.
- Q89725043 P2860 Q89725043-DEB31054-F8F8-438C-8A32-BEF7DA2D4151 @default.
- Q89725043 P304 Q89725043-5BE357FD-8192-46F6-8320-566B60ADB104 @default.
- Q89725043 P31 Q89725043-2BBBF86A-AB58-47A4-A1BC-706E6CB0B7B9 @default.
- Q89725043 P356 Q89725043-097751A9-C17A-4EA5-B7C8-CBF354D5E57F @default.
- Q89725043 P433 Q89725043-5DB286F5-FD03-4A27-9B14-93FB955B8467 @default.
- Q89725043 P478 Q89725043-85CEC249-4687-4974-93FA-8F0239D96634 @default.
- Q89725043 P577 Q89725043-421893FB-7CC9-499C-8504-C46F36FE2BAB @default.
- Q89725043 P698 Q89725043-807A96F4-9863-4A32-97C0-8EB837D8CA34 @default.
- Q89725043 P921 Q89725043-E98F3D85-1515-44A4-9A10-48B912AE41B7 @default.
- Q89725043 P932 Q89725043-8E279140-6EDA-4A41-A788-3EC447D6E2B4 @default.
- Q89725043 P356 S11523-020-00702-4 @default.
- Q89725043 P698 32060867 @default.
- Q89725043 P1433 Q25378200 @default.
- Q89725043 P1476 "Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer" @default.
- Q89725043 P2093 "Alejandro Navarro" @default.
- Q89725043 P2093 "Alice T Shaw" @default.
- Q89725043 P2093 "Antonello Abbattista" @default.
- Q89725043 P2093 "Enriqueta Felip" @default.
- Q89725043 P2093 "Gerson Peltz" @default.
- Q89725043 P2093 "Holger Thurm" @default.
- Q89725043 P2093 "Justin F Gainor" @default.
- Q89725043 P2093 "Melissa L Johnson" @default.
- Q89725043 P2093 "Todd M Bauer" @default.
- Q89725043 P2093 "Yazdi K Pithavala" @default.
- Q89725043 P2860 Q27690215 @default.
- Q89725043 P2860 Q27851710 @default.
- Q89725043 P2860 Q27853101 @default.
- Q89725043 P2860 Q27853367 @default.
- Q89725043 P2860 Q33804619 @default.
- Q89725043 P2860 Q35057308 @default.
- Q89725043 P2860 Q35549714 @default.
- Q89725043 P2860 Q35858617 @default.
- Q89725043 P2860 Q36469191 @default.
- Q89725043 P2860 Q37350770 @default.
- Q89725043 P2860 Q37442859 @default.
- Q89725043 P2860 Q37646794 @default.
- Q89725043 P2860 Q37690485 @default.
- Q89725043 P2860 Q38085875 @default.
- Q89725043 P2860 Q39105350 @default.
- Q89725043 P2860 Q39285861 @default.
- Q89725043 P2860 Q39354188 @default.
- Q89725043 P2860 Q41614759 @default.